Evidence map›Paper›PMID 39468018›Full record

Trial reportThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2024

Approaches and processes for paediatric chest X-ray classification used in the SHINE TB treatment-shortening trial.

M Palmer, M M van der Zalm, H S Schaaf, P Goussard, J Morrison, J A Seddon, S Hissar, D Baskaran, A Kinikar, P Raichur and 7 more

Abstract readRandomized Controlled TrialClinical Trial, Phase III
In one paragraph

Trial report in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

M PalmerDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
M M van der ZalmDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
H S SchaafDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
P GoussardDepartment of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
J MorrisonDepartment of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
J A SeddonDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa;, Department of Infectious Disease, Imperial College London, London, United Kingdom.
S HissarNational Institute for Research in Tuberculosis, Chennai, India.
D BaskaranNational Institute for Research in Tuberculosis, Chennai, India.
A KinikarB.J. Government Medical College, Pune, India.
P RaichurB.J. Government Medical College, Pune, India.
E WobudeyaMakerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.
C ChabalaUniversity Teaching Hospital, Lusaka, Zambia.
K LebeauMedical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
A M CrookMedical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
A TurkovaMedical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
D GibbMedical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
A C HesselingDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.

Funding

The long-term consequences of pulmonary tuberculosis and respiratory viruses on lung health in young South African childrenK43TW011028 · FIC · STELLENBOSCH UNIVERSITY · PI VAN DER ZALM, MARIEKE MARGREET · 2020 to 2024
$647k
FIC NIH HHS K43 TW011028Medical Research Council MC_UU_00004/04Wellcome Trust
6 · The paper itself

Abstract

<sec><title>INTRODUCTION</title>SHINE (Shorter Treatment for Minimal Tuberculosis in Children) was the first Phase 3 paediatric TB treatment-shortening trial. Robust chest X-ray (CXR) classification methods were integral to excluding severe disease for trial eligibility and to retrospectively adjudicating TB status at baseline. We describe and critically evaluate the CXR classification approaches and processes used in the SHINE trial.</sec><sec><title>METHODS</title>Children with non-severe TB were randomised to 4- vs 6-months anti-TB treatment. Radiologically non-severe TB was defined on CXR. CXRs were systematically interpreted by on-site clinicians prospectively for eligibility determination and retrospectively by experts to inform adjudication of baseline TB status and disease severity.</sec><sec><title>RESULTS</title>A screening CXR was successfully obtained from all 1,204 enrolled children; 1,134 CXRs from children with intra-thoracic TB were reviewed by expert readers. Compared with the expert panel, enrolling clinicians classified more CXRs as abnormal and 'typical TB' and all as radiologically non-severe. The expert panel retrospectively classified 71/1,134 (6%) CXRs as severe. Of these, 4 (5.6%) had unfavourable outcomes compared with 34 (3.0%) in the trial overall.</sec><sec><title>DISCUSSION</title>Using CXRs to classify radiological disease severity and inform eligibility decisions in real-time by local enrolling clinicians was feasible and safe in this large paediatric TB trial. Retrospective central expert CXR review was successful. Refinement of the CXR methods for the classification of both disease severity and TB status could support standardised implementation in routine care and research.</sec>.

Indexed as

Antitubercular AgentsRadiography, ThoracicTuberculosis, PulmonaryChildChild, PreschoolFemaleHumansInfantMaleProspective StudiesRetrospective StudiesSeverity of Illness IndexTime FactorsAntitubercular Agents

Identifiers

PMID39468018
PMCPMC7617470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.